Rigel Pharmaceuticals, Inc. (RIGL) key performance indicators and operating metrics (15 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Net Product Sales - Tavalise | 37.3M | FY2026-Q1 |
| Net Product Sales - ResLydia | 8M | FY2026-Q1 |
| Contract Revenues From Collaborations | 3.9M | FY2026-Q1 |
| Net Product Sales - Gavretto | 9.6M | FY2026-Q1 |
| Net Product Sales | 54.92M | FY2026-Q1 |
| Median Number of Prior Therapies | 3.00 | FY2025-Q3 |
| Patients Enrolled | 33.00 | FY2025-Q3 |
| Patients Receiving Luspatercept (Percent) | 76.00 percent | FY2025-Q3 |
| Patients With High Transfusion Burden at Baseline (Percent) | 61.00 percent | FY2025-Q3 |
| Rezlidhia Bottles Shipped to Patients and Clinics | 503.00 | FY2024-Q4 |
| Rezlidhia Total Bottles Shipped | 565.00 | FY2024-Q4 |
| Tavalise Bottles Shipped to Patients and Clinics | 2.86K | FY2024-Q4 |
| Tavalise Total Bottles Shipped | 3.17K | FY2024-Q4 |
| Gavreto Bottles Shipped to Patients and Clinics | 874.00 | FY2024-Q4 |
Back to RIGL overview · RIGL earnings · RIGL holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.